恩度联合顺铂心包腔内注射治疗恶性心包积液临床研究

摘要

目的 观察重组人血管内皮抑素(国产,商品名恩度)联合顺铂心包腔内灌注治疗肺癌合并恶性心包积液的疗效和安全性.方法 67例肺癌合并心包积液患者分为Ⅰ、Ⅱ组,分别注入重组人血管内皮抑素及重组人血管内皮抑素加顺铂联用,每周1次,连用3周后评价疗效及生活质量.结果 两组治疗心包积液控制总有效率比较无统计学差异(P>0.05),与文献报道比较亦无明显差异;但Ⅱ组完全缓解率高于Ⅰ组及文献报道(P<0.05).结论 恩度联合顺铂治疗肺癌合并恶性心包积液疗效显著,不增加化疗的毒副作用,值得临床推广应用.%Objective To evaluate the effect and safety of Endostatin and PDD in the treatment of the patients with lung cancer combining malignan Hydropericardium by Pericardial injection. Methods 67 patients with lung cancer combining Hydropericardium were randomly divided into 2 groups. The patients in the research group Ⅰ was treated only by injection of Endostar and those in group Ⅱ were treated by Endostar and PDD, The above medicine was given one time every 7 days for 3 weeks, evaluate therapeutic effect and the quality of life(QOL) and compared with literatures reports. Results The total effective rate of two groups total effectiveness has no statistical significance( P ＞ 0.05 ), and also has no obvious difference compared with literatures reports; the CR rate of group Ⅱ is higher than group Ⅰand literatures reports( P ＜ 0.05 ). Conclusion Endostatin Combined With Cisplatin has remarkable curative effect for treating Lung Cancer combining malignan Hydmpericardium, Medicines don't increase the side effects , and worth to be widely spread.